股市资讯 | 财报强劲推动股价,阿里巴巴市值赶超腾讯。金贷监管风暴降临,蚂蚁金服能否延续独角兽神话

wechat omage

美国股市

北京时间5月5日凌晨,美股收高,科技股领涨,道指大涨逾330点创3周来最大单日涨幅。巴菲特增持苹 果的消息推动苹 果股价创历史新高。投资者正在权衡美国非农就业数据以及阿里巴巴等财报。北京时间5月5日04:00,道指涨332.36点,或1.39%,报24262.51点;标普500指数涨33.69点,或1.28%,报2663.42点;纳指涨121.47点,或1.71%,报7209.62点。

个股财报表现(选)

阿里巴巴:

昨日晚间,阿里巴巴发布了2018财年第四季度以及全年业绩财报,2018财年阿里巴巴集团收入2502.66亿元,同比增长58%。核心电商业务收入2140.20亿元,同比增长60%。净利润为人民币832.14亿元,同比增长44%。

2018财年第四季度,阿里巴巴收入达619.32亿元,同比增长61%,其中,核心电商收入达512.87亿元,同比增长62%。净利润为人民币140.99亿元,同比增长35%。中国零售平台的年度活跃消费者达到5.52亿,较截至2017年12月底止的12个月增长3700万,季度内新增年度活跃消费者数创下IPO以来最高值。

值得关注的是,阿里巴巴还在财报中首次公布了支付宝全球活跃用户数量:

在截至2018年3月31日的财年中,支付宝与其全球合资伙伴一起,为全球约8.7亿名年度活跃用户提供了服务。截至2018年3月,蚂蚁金服还通过贷款、现金管理和保险服务为逾1500万家小企业提供服务。

得益于良好的财报,阿里巴巴隔夜暴涨3.53%,最新市值达到4778亿美金,超过腾讯的4634亿美金,位居国内公司市值第一位。按照6.3589的汇率计算,折合30382亿人民币。与A股大市值公司相比,阿里巴巴的市值,约等于1.5个工行、两个中石油、3个平安、4个茅台。

伯克希尔哈撒韦:九年来首度亏损! 一季度亏损11.4亿美元

北京时间周六晚间,伯克希尔哈撒韦发布2018年一季报。

财报显示,该公司一季度投资亏损62.63亿美元,衍生品亏损1.63亿美元,经营利润盈利52.88亿美元,合计亏损11.38亿美元。公司解释称,之所以一季度会发生明显亏损,主要是由于会计准则的改变。新版的会计准则要求将未实现利润或亏损计入到股票投资的利润或亏损中,由此带来了财报数据上的亏损。

当季,伯克希尔保险承销业务收入为4.07亿美元,去年同期为亏损2.67亿美元。保险投资收入为10.12亿美元,同比增加11.5%;铁路、公用设施和能源业务运营收入17.3亿美元,同比增加31.3%;其他业务收入21.96亿美元,同比增加36.6%。

香港股市

截至北京时间4日收盘,恒指跌1.28%,报29926点,失守3万点大关;国企指数跌1.07%,报11890点;红筹指数跌0.73%,报4429点;大市全天成交989亿港元。

内银股继续低迷,截至4日收盘,中国银行(03988)跌0.96%,建设银行(00939)跌1.11%,工商银行(01398)跌1.47%,农业银行(01288)跌1.14%,招商银行(03968)跌1.51%。

券商股普遍下跌;华泰证券(06886)跌2.13%,中信证券(06030)跌1.69%,海通国际(00665)跌2.2%,中国银河(06881)跌1.39%,申万宏源(00218)跌2.08%。

内地汽车制造股再次走低,北京汽车(01958)跌1.82%,长城汽车(02333)跌0.99%,比亚迪(01211)跌3.53%,华晨中国(01114)逆市涨4.76%,广汽集团(02238)报13.46港元。

平安好医生 :上市首日死守发行价

由中国平安分拆的“独角兽”平安好医生今日在港交所主板挂牌上市,高开近5%,随后涨幅收窄,截至收盘平安好医生平收,死守首发价54.8港元。平安好医生上市共发售1.6亿股,并已引入7名基础投资者,包括黑石基金、美国共同基金(CRMC)、GIC、加拿大退休金计划投资委员会、马来西亚国家主权基金国库控股全资拥有的Pantai Juara、泰国正大光明控股及瑞士再保险共认购7879万股。

中国股市

北京时间5月4日受石油、钢铁、券商、银行等权重股回调所影响,两市均呈弱势震荡整理走势,中小板表现较强。医药板块表现抢眼,经过昨天短暂休整之后,今日再度带头上攻,板块整体涨幅创近3年来新高,题材股未能延续昨日强势表现清淡。截止收盘,沪指跌0.32%,报3091点;深成指跌0.31%,报10426点;创业板指跌0.65%,报1814点。从盘面上看,医药、种植业与林业、军工、电力、养殖业等板块涨幅居前;石油、钢铁、券商、银行、物流、家电等板块跌幅居前。沪股通净流出4亿,深股通净流出7.8亿。

热点板块:

1、医药板块

医药股午后逆势拉升,板块整体涨幅近2%,创近3年来新高,普利制药、长春高新、科伦药业、通化东宝、华海药业、沃森生物等一批医药股股价创出历史新高。

2、农业股

农业股尾盘逆市走强,宏辉果蔬、香梨股份、万向德农、北大荒、敦煌种业等均有不同程度的涨幅。

蚂蚁金服:最大独角兽新一季度首见亏损,估值反升

据阿里巴巴2018财年最新一季度财报显示,继截至去年12月的季度利润暴跌后,蚂蚁金服在截至三月底的季度出现净亏损。对于亏损,财报解释是因为蚂蚁金服继续加大投资,从而实现了用户的强劲获取和参与,而这些投资导致蚂蚁金服本季度出现净亏损。

材料显示,蚂蚁金服的税前利润在2017年二、三季度均超过50亿元,但在四季度则环比大幅缩水九成,这除了支付补贴战的影响,很可能与四季度的现金贷整治有关——受监管风暴影响,借呗和花呗的ABS发行出现暂缓,最终波及到消费金融业务的扩张步伐。

巴克莱银行经实地考察并重新进行业务分析和估值计算后,决定对蚂蚁金服的估值由1060亿美元上调至1550亿美元,上调幅度达46.23%。

巴克莱表示,其上调估值的主要原因具体来自两个方面:

首先,蚂蚁在过去一年线下支付增长迅速;

其次,受益于多样化的支付场景和其他金融服务的渗透,蚂蚁金服的收入来源更加丰富;同时,消费者使用更多类别的金融服务,一体化金融服务的渗透促进ARPU提升。

关键词:股票,香港股市,港股,恒指,香港IPO,交易港股,美股,中国A股,股市资讯, 美国上市, 阿里巴巴股票,行业板块,银行股,特斯拉,暗盘,上市,高盛,美国IPO, 蚂蚁金服,蚂蚁金融,高盛,黑石,中方博鳌论坛,华尔街,特朗普的推特,股市警报,万科集团,碧桂园,融创中国,芯片,苹果股票,美国国债,高盛股票,上市制度改革,微软,百度,爱奇艺
来源:东方财富网,新浪财经,同花顺,21世纪经济报道,彭博,华尔街见闻,辉立证券

联系我们开设账户

需要帮助吗?请分享您的详细资料,我们会给您答复。

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com